SPECIAL REPORT
MOST SHARED
- How Boaz Weinstein and Hedge Funds Outsmarted JPMorgan
- JPMorgan Trading Loss: Did Regulators Miss the Risk?
- RIM May Cut at Least 2,000 Jobs in Restructuring: Report
- Marc Faber: 100% Chance of Global Recession
- As Bank Loans Dry Up in Spain, Small and Medium Businesses Fight for Life
- How Nasdaq Lost Control of Facebook IPO, by the Minute
- Citigroup Lost $20 Million on Facebook IPO Trades
- The Biggest Market Myth There Is?
- Judge Says Skilling Can Seek New Trial
- What College Tuition Will Look Like in 18 Years
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
- How Nasdaq Lost Control of Facebook IPO, by the Minute
- Week Ahead: Europe Has Wall Street Bull on Short Leash
- Pro-Bailout Greeks Regain Lead in Polls Before Vote
- Citigroup Lost $20 Million on Facebook IPO Trades
- JPMorgan to Shake Up Risk Team After Big Loss: Report
- RIM May Cut at Least 2,000 Jobs in Restructuring: Report
- EU Finalizes Bank Reforms; Shifts Burden to Bondholders
- Spain's Bankia Eyes Stake Sales After Record Bailout
- EU Set to Launch Action Against China Over Telecom Aid
RSS FEED
Pharma's Market
Text Size 
It's Diabetes Drug Days
 |
Pills |
An estimated 20 million or so Americans have the disease, which many experts call an epidemic. It costs this country tens of billions of dollars a year to deal with it. And several biopharma and monitoring device companies are racing to grab a bigger piece of this fast-growing, sugar-free pie.
Yesterday, Eli Lilly, Amylin and Alkermes announced that once-a-week Byetta, which is in late-stage testing, lowered blood sugar more than pills—Merck's Januvia and Takeda's Actos. Today, an FDA advisory committee is looking at a potential competitor to the MRK drug from Bristol-Myers Squibb and AstraZeneca called Onglyza. It's what's referred to as a "me-too" product in the industry because it's really not all that different from Januvia.
Tomorrow, though, the same FDA panel takes up a first-ever one-a-day injection called Victoza from diabetes drug kingpin NovoNordisk. Shares of NVO are bouncing back today after falling yesterday on investor jitters following the release of the agency briefing documents for Thursday's meeting. Many analysts cited the FDA's concern over a very small number of cases of thyroid tumors in people and lab rats that got Victoza. David Kliff, a type-2 diabetic who writes "The Diabetic Investor" newsletter says, "It wouldn't surprise Diabetic Investor at all if the FDA asked the company (NVO) to conduct another pre-approval study."
But it's important to point out that handicapping FDA panel votes is very risky business.
It ain't over until the fat lady sings. And remember that advisory committees simply make recommendations to the FDA and the agency doesn't always follow their outside experts' advice. The outcome of the Novo vote could have an impact on GlaxoSmithKline and Roche, which are both working on similar drugs. But the nearest-term potential competitor is once-a-week Byetta, which if it's safe and effective, some analysts think would trump NVO's one-a-day.
The global diabetes market pie is big and getting bigger by the day. The brewing battle over which companies will get the biggest piece is going to be a sweet story to cover.
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes
